Educational  ·  Mechanism-Led

The Wolverine Stack, what the science actually shows

The Wolverine Stack is a combination of BPC-157 and TB-500 used together for tissue repair and recovery. Neither compound is FDA-approved; the combination has not been studied in any clinical trial. Evidence base: strong individual animal data for each compound; no published human combination trials.

BPC-157 and TB-500 stacked together. The most-discussed peptide combination in biohacking. Strong individual animal data for each compound. Zero human combination trials. Here is the evidence, honestly rated.

2
Compounds stacked
0
Human combo trials
Not
FDA approved
Scroll
On this page
  1. What the Wolverine Stack is
  2. Mechanism, in plain English
  3. What the evidence shows for each compound
  4. FDA status
  5. Common synonyms researchers use
  6. Safety and adverse-event landscape
  7. Frequently asked questions
Mechanism
BPC-157: local repair via NO/VEGFR2 signaling. TB-500: systemic repair via actin regulation and cell migration. Combined: theoretical complementary mechanisms.
Evidence Level
Primarily preclinical (★★☆☆☆). Strong individual animal data for each compound. No published human combination trials.
FDA Status
Neither BPC-157 nor TB-500 is FDA-approved. Both are research compounds. The combination has not been studied in any clinical trial.
Common Synonyms
Wolverine Stack, BPC-157 + TB-500, healing stack, recovery stack, tissue repair stack
Last Reviewed
August 19, 2026

What the Wolverine Stack is

The "Wolverine Stack" is a colloquial name for the combination of BPC-157 and TB-500 (a synthetic analog of Thymosin Beta-4). The name comes from the comic-book idea of rapid tissue regeneration. And it tells you something about the hype level around this combination.

BPC-157 is a 15-amino-acid peptide fragment originally isolated from gastric juice, studied in animal models for tendon, vascular, and gut tissue repair. TB-500 is a synthetic version of the active region of Thymosin Beta-4, studied for its role in cell migration, blood vessel formation, and tissue remodeling.

The theory behind stacking them: BPC-157 works locally at the injury site (upregulating repair signals), while TB-500 works systemically (promoting cell migration to damaged areas). Together, they would theoretically cover both local and systemic repair pathways. This is a reasonable hypothesis. But hypothesis is where the evidence stops.

The name tells you the problem. Wolverine is fiction. The stack is based on individual compound animal data and a logical but untested hypothesis about synergy. Nobody has studied this combination in a human trial.

Peptexa editorial note

Mechanism, in plain English

Each compound has its own mechanism. The combination hypothesis is based on complementary pathways.

NO
BPC-157: modulates nitric oxide signaling, vascular tone and local tissue repair
VEGF
BPC-157: upregulates VEGFR2, new blood vessel formation at injury sites
Actin
TB-500: regulates actin polymerization, cell structure, migration, and wound closure
Migrate
TB-500: promotes cell migration to damaged tissue, systemic repair signaling

Want all 31 Muscle Recovery & Healing compounds in one place?

The Peptexa Muscle Recovery & Healing guide covers every compound in this category, mechanism, evidence level, and FDA status for each.

Get the Guide →

What the evidence shows for each compound

BPC-157 (individually): Extensive animal data across tendon transection, vascular ligation, NSAID-induced gut damage, and colitis models. Effects reported as positive. The most-cited review is Sikiric (2018). Human published data is limited to small case-series and registry submissions. No large human RCTs.

TB-500 (individually): Animal data shows promotion of wound healing, hair regrowth, and cardiac repair in rodent models. Thymosin Beta-4 (the parent molecule) has been studied in human clinical trials for wound healing and cardiac applications, but TB-500 itself has no published human RCTs.

The combination: No published study. Animal or human, has tested BPC-157 and TB-500 together. The "stack" is entirely community-driven, based on individual compound data and a reasonable but untested mechanistic hypothesis.

Combined evidence rating: ★★☆☆☆, primarily preclinical, with no combination-specific data.

Stacking two research compounds with no combination data is not evidence-based medicine. It is an experiment performed on the user. That does not make it wrong, it makes the evidence level something you should understand clearly before deciding.

Peptexa editorial note

FDA status

Neither BPC-157 nor TB-500 is FDA-approved for any human indication. Both are classified as research compounds.

BPC-157 is under FDA advisory review (July 2026) for potential compounding access. TB-500 (Thymosin Beta-4) is classified as a WADA-prohibited substance. Neither is available through standard prescription pathways. Last reviewed 2026-08-19.

Common synonyms researchers use

Wolverine Stack · BPC-157 + TB-500 · BPC/TB stack · Healing stack · Recovery stack. Also: Body Protection Compound 157 + Thymosin Beta-4 fragment.

Safety & adverse-event landscape

Individual safety profiles: BPC-157 has been administered to rodents without reported mortality. TB-500 (Thymosin Beta-4) has been tested in limited human wound-healing trials without major adverse events reported. However, combination safety has never been studied.

Both compounds are WADA-prohibited for in-competition athletic use. BPC-157 modulates nitric oxide pharmacology (theoretical interaction with cardiovascular drugs). The combination adds unknown interaction risks.

Peptexa is an educational resource. We do not provide dosing guidance, sourcing recommendations, or protocol advice. Always consult a qualified healthcare provider before any decision involving a peptide or therapeutic compound.

Frequently asked questions

The Wolverine Stack is a colloquial term for combining BPC-157 and TB-500, two research peptides used together for tissue repair. The name references rapid healing. No human combination trials exist.
No. Peptexa is educational only. We do not sell or ship any peptide product.
There is no direct evidence for the combination. Each compound has individual animal data supporting tissue repair mechanisms. The hypothesis that they work better together is reasonable but untested in any published study.
No. Neither BPC-157 nor TB-500 is FDA-approved for any indication. The combination has never been studied in a clinical trial.
Yes. Both BPC-157 and TB-500 (Thymosin Beta-4) are classified as WADA-prohibited substances for in-competition athletic use.

Want this in your inbox weekly?

Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.

The full Muscle Recovery & Healing reference

31 compounds. Mechanism, evidence level, and FDA status for every one.

Get the Muscle Recovery & Healing Guide →